Ying Meng - research works

From 2017 to 2022, the proportion of EoL ICU admissions increased from 0.9% to 2.8%, aggressive chemotherapy use rose from 4.1% to 4.8%, and multiple hospitalisations increased from 16.2% to 18.3%.

Male sex, younger age, stable income, social health insurance with higher reimbursement rates, and comorbidities were factors significantly associated with a higher risk.

The cumulative obliteration rate was 37% at 5 years and 56% at 10 years.

Patients with a nidus volume of ≤ 10 cm3 had significantly higher cumulative obliteration rates than those with a nidus volume > 10 cm3 (log-rank test, p = 0.021).

Similarly, patients treated with a prescription dose > 17 Gy showed significantly higher cumulative obliteration rates compared to those treated with a dose ≤ 17 Gy (log-rank test, p = 0.012).

The cumulative 5-year incidences of hemorrhage and RICs following VS-SRS were 19% and 7%, respectively.

Time-dependent AUC was 0.895 (95% CI 0.828-0.959) at 12 months, 0.897 (95% CI 0.833-0.952) at 24 months, and 0.934 (95% CI 0.889-0.969) at 60 months.

IBS (0-60 months) was 0.050 with favorable calibration.

Actuarial 1-, 5-, and 10-year OS was 98.2%, 93.6%, and 85.2%, and PFS was 92.4%, 73.6%, and 64.8%.

Mixed solid-cystic phenotype had worse LC than non-mixed tumors (log-rank p = 0.025); non-mixed phenotype remained independently associated with improved LC (HR 0.53, p = 0.026).

Visual fields improved in 10%, were unchanged in 86%, and deteriorated in 4%; visual acuity improved in 6%, was unchanged in 91%, and worsened in 3%.

Ten-year freedom from endocrine deterioration was 96.7%.